Summary Cellular oncogenes have been identified by the biological activity of tumour DNAs in transfection assays and/or by homology to the transforming genes of retroviruses. In some tumours, the biological activity, organization or expression of these genes is altered, suggesting that such alterations contribute to the development of neoplastic disease. Experiments leading to the identification of cellular oncogenes are reviewed and our current understanding of the mechanisms by which they induce transformation of cells in culture and may contribute to the pathogenesis of neoplasms in vivo is discussed.
Detection of cellular transforming genes by transfection
The biological activity of tumour DNAs, detected by transfection of NIH 3T3 mouse cells, has led to the identification of transforming genes which are activated in a variety of human and animal neoplasms. The basic observation is that DNAs of many tumours induce transformation of NIH 3T3 cells with high efficiencies. In contrast, DNAs of normal cells lack efficient transforming activity, including normal DNAs of the same individual animals or patients whose tumour DNAs induce transformation. These findings imply that the development of many neoplasms involves dominant genetic alterations leading to the activation of transforming genes which are then detectable by their biological activity in this gene transfer assay.
The transfection assay for cellular transforming genes is based on work of Hill & Hillova (1972) , who demonstrated transfer of biologically active proviral DNA from cells infected with Rous sarcoma virus. Improvements in the transfection technique, including the use of NIH 3T3 cells as recipients which efficiently integrate exogenous DNA, have allowed extension of this approach to cellular, in addition to viral, transforming genes.
The initial observations of transforming genes of cellular origin demonstrated transformation of NIH 3T3 cells by DNAs of some chemically-transformed mouse cell lines and by DNA fragments of normal cells (Cooper et al., 1980) . High molecular weight DNAs of normal cells lacked transforming activity Cooper et al., 1980) , whereas DNAs of some chemicallytransformed cells induced transformation with 0.1-1 transformants jg-1 DNA . In addition, DNA fragments (0.5-5 kb) of normal *Delivered at the 25'UL Annual General Meeting of the British Association for Cancer Research, Manchester, April, 4, 1984. chicken and mouse cells induced transformation with low efEfciency (0.003 transformants ig-1 DNA) (Cooper et al., 1980) . DNAs of NIH cells transformed by these normal cell DNAs induced transformation with high efficiencies in secondary transfection assays (0.1-1 transformants ug-1 DNA), indicating that these transformed cells contained activated transforming genes, presumably generated by DNA rearrangements during the primary DNA integration process (Cooper et al., 1980) . These experiments have recently been confirmed and extended to fragments of normal human DNA (Schafer et al., 1984) . In addition to demonstrating the utility of the transfection assay for detection of cellular transforming genes, these experiments indicated that (i) normal cells contained genes which were potentially capable of inducing transformation and (ii) some chemicallytransformed cells contained activated genes which induced transformation with high efficiencies.
Application of this approach to naturally occuring tumours initially led to the identification of activated transforming genes in chicken B cell lymphomas (Cooper & Neiman, 1980) , a human bladder carcinoma cell line (Krontiris & Cooper, 1981; Shih et al., 1981) and carcinogen-induced rodent carcinomas and neuroblastomas (Shih et al., 1981) . Subsequently, activated transforming genes have been detected in many different types of neoplasms (carcinomas, sarcomas, neuroblastomas, melanomas, lymphomas and leukaemias) of human, rodent and avian origin. Some of the transforming genes identified by this approach are related to the ras genes of Harvey and Kirsten sarcoma viruses, whereas others are unrelated to previously described retroviral transforming genes.
Distribution of activated genes in neoplasms
Three different members of the ras gene family have been identified as biologically active (9 The Macmillan Press Ltd., 1984 transforming genes in neoplasm DNAs: rasH, ras and rasN (Der et al., 1982; Parada et al., 1982; Santos et al., 1982; Hall et al., 1983; Shimizu et al., 1983b) (Table I) (Cooper & Neiman, 1980; Lane et al., 1982b; Diamond et al., 1983) . However distinct transforming genes are activated in T cell neoplasms (Tlym-I and tx-3) and in B cell neoplasms representing other stages of B lymphocyte differentiation (tx-I in pre B cell neoplasms and tx-2 in myelomas and plasmacytomas) ( Table I) (Lane et al., 1982b . The activation of these transforming genes appears specific to neoplasms representing discrete stages of B and T lymphocyte differentiation and occurs in the majority (80-100%) of individual neoplasms of the appropriate cell type (Lane et al., 1982b) . The spectrum of activation of these genes in neoplasms thus suggests that they play a more reproducible role in the development of specific types of tumours than the ras genes.
Ras gene activation and function The ras genes all encode proteins of approximately 21,000 daltons which are designated p21s. Experimental manipulations of the normal human rasH gene have shown that over-expression of the normal gene product is sufficient to induce cell transformation (Chang et al., 1982) . However, activation of ras genes in human tumours is commonly a consequence of structural, rather than regulatory, mutations Reddy et al., 1982; Taparowsky et al., 1982 Taparowsky et al., , 1983 ; Der & Cooper, 1983; Capon et al., 1983a, b; Shimizu et al., 1983a Shimizu et al., , 1983a Yuasa et al., 1983) . The mutations in tumours which have been analyzed to date alter either codon 12 or codon 61. At either of these positions, substitution of multiple different amino acids is sufficient to endow p21 with transforming activity. In addition, most activating mutations appear to induce conformational alterations in p21 which are detectable by abnormal electrophoretic mobilities Der & Cooper, 1983; Yuasa et al., 1983) . Taken together, these observations suggest that substitution of a variety of abnormal amino acids at these critical loci may inactivate a regulatory domain of p.21, thus resulting in abnormal p21 function in vivo.
Studies of viral ras proteins have indicated that they are localized to the inner face of the plasma membrane (Willingham et al., 1980; Furth et al., 1982) and modified by acylation (Sefton et al., 1982) . The only established biochemical activity common to all viral ras transforming proteins binding is guanine nucleotide binding (Scolnick et al., 1979 , Furth et al., 1982 .
To attempt to elucidate the biochemical basis for the transforming activity of mutant p2ls in human tumours, we have compared the biochemical properties of p21s encoded by normal and activated human ras genes. These experiments indicated that both normal and transforming human p21s were localized to the plasma membrane and were modified to similar extents by post-translational acylation (Finkel et al., 1984) . Neither normal nor activated p2ls were glycosylated or phosphorylated (Der & Cooper, 1983; Finkel et al., 1984) . Thus the subcellular localization and post-translational processing of human p2ls were not altered by ras gene activation.
Since guanine nucleotide binding represented the only biochemical activity of p21, we investigated the possibility that the affinity or specificity of p21 for nucleotides was altered as a consequence of mutational activation. However, the GTP binding affinities of both normal and activated human p2ls were indistinguishable (KD'S of 1-2 x 10-8 M) and both the normal and activated proteins were specific for GTP and GDP binding (Finkel et al., 1984) . Thus mutational activation of p21 does not directly affect its intrinsic nucleotide binding properties.
In order to investigate the physiologic function of ras proteins, we have attempted to identify other cellular proteins with which p21 might interact (Finkel & Cooper, 1984 (Gilman, 1984) .
Blym transforming genes
The Blym-1 transforming' gene was initially identified in DNAs of chicken B cell lymphomas (Cooper & Neiman, 1980) and was isolated as a molecular clone by sib-selection (Goubin et al., 1983) . The cloned chicken Blym-J gene was unusually small (only 600 nucleotides) and its nucleotide sequence indicated that it encoded a small protein of 65 amino acids (Goubin et al., 1983) . Comparison of the predicted chicken Blym-J amino acid sequence with sequences of known cellular proteins revealed partial homology (36%) between the chicken Blym-1 protein and the aminoterminal region of transferrin family proteins (Goubin et al., 1983) . This homology was concentrated in regions which were conserved between different members of the transferrin family, suggesting a common ancestry for chicken Blym-J and a region of the transferrins, as well as stimulating the speculation that this homology might also suggest a functional relationship.
Blot hybridization analysis indicated that the chicken Blym-J gene was a member of a small family of related genes which were present in human as well as (Hayward et al., 1981) . Blym-J and myc are unrelated to each other and are not closely linked in cellular DNA (Cooper & Neiman, 1981) . Thus, their co-activation in these neoplasms represents two distinct events. Since both genes are reproducibly activated in the vast majority (90%) of individual lymphomas, both appear to play important roles in the disease process.
Human myc and Blym-1 genes are also both activated in Burkitt's lymphomas. In this disease, human myc is translocated from chromosome 8 to an immunoglobulin locus (Dalla-Favera et al., 1982; Taub et al., 1982) . In the same tumours, human Blym-J, which is located on chromosome 1 (Morton et al., 1984) , is detected as an active transforming gene in the transfection assay (Diamond et al., 1983) . Thus the same two oncogenes are involved in B cell lymphomas of both chicken and man. The reproducible activation of both myc and Blym in this disease in two different species presents a strong argument for the causal role of both genes in the disease process.
The initial stage in the pathogenesis of B cell lymphomas in the chicken is the outgrowth of preneoplastic transformed lymphoid follicles (Neiman et al., 1980) . Approximately 10-100 such hyperproliferative lesions are observed out of^105 lymphocyte follicles in the bursa. These preneoplastic follicles retain the organization of normal lymphoid follicles and the majority appear to regress under the normal physiological controls which mediate regression in the bursa. However, a small fraction (<5%) of these pre-neoplastic follicles are instead thought to progress to clonal neoplasms (Neiman et al., 1980) . Activation of both myc and Blym-J has occurred in the earliest detectable clonal bursal neoplasms (Cooper & Neiman, 1981 (Lane et al., 1982a) . Abelson virus induced mouse pre-B cell lymphomas involve the viral abl gene as well as a distinct and unlinked NIH 3T3 transforming gene (tx-1) (Lane et al., 1982b) . Murine leukaemia virus-induced T cell lymphomas and mouse mammary tumour virusinduced carcinomas involve activation of genes by virus integration (MLVI and MM-TVint) (Tsichlis et al., 1983; Nusse & Varmus, 1982; Peters et al., 1983) and of unrelated transforming genes detected by transfection (Tlym-I and tx-4) (Lane et al., 1981 
